Effects of neo-adjuvant chemotherapy combined with modified radical mastectomy on clinical effect and tumor markers in patients with breast cancer

doi:10.12092/j.issn.1009-2501.2018.01.020

Abstract

Abstract:

AIM: To investigate the effects of neo-adjuvant chemotherapy combined with modified radical mastectomy on clinical effect and tumor markers in patients with breast cancer. METHODS: According to chemotherapy regimens, a total of 88 advanced colorectal cancer patients were divided into TE group (46 cases) and FEC group (42 cases) from August 2013 to February 2015. All patients received 4 cycles of chemotherapy (1 cycle=21 d). Changes of immune function, MMP and VEGF, adverse reaction and survival situation in two groups were observed and compared. RESULTS: Total lymphocytes, T lymphocyte, helper T lymphocyte and cytotoxic T lymphocyte of TE group had no significant difference before chemotherapy and after chemotherapy (P>0.05); T lymphocyte, and cytotoxic T lymphocyte of FEC group had no significant difference before chemotherapy and after chemotherapy (P>0.05); total lymphocytes and helper T lymphocyte of FEC group decreased significantly after chemotherapy (P<0.05); total lymphocytes and helper T lymphocyte of FEC group were significantly lower than those in TE group (P<0.05); MMP-2 and MMP-9 of two groups decreased significantly after chemotherapy (P<0.05); MMP-2 and MMP-9 of TE group were significantly lower than those in FEC group (P<0.05); VEGF-A and VEGF-B of two groups decreased significantly after chemotherapy (P<0.05); VEGF-A and VEGF-B of TE group were significantly lower than those in FEC group (P<0.05); incidence rate of adverse reactions of TE group was 4.35%, which was 16.67% of FEC group, there was no significant difference between TE group and FEC group (P>0.05); Followed up for 2 years, survival rate of TE group was 84.78%, incidence rate of adverse reactions of FEC group was 64.29%, survival rate of TE group was significantly higher than that in FEC group (P<0.05). CONCLUSION: neo-adjuvant chemotherapy combined with modified radical mastectomy has little influence on immune function and fewer adverse reactions, which can restrain MMP and VEGF, and improve survival rate in patients with breast cancer.

Key words: neo-adjuvant chemotherapy, modified radical mastectomy, immune function, MMP, VEGF

CLC Number:

R737.9

LUO Yong, LI Qi, HUA Tebo. Effects of neo-adjuvant chemotherapy combined with modified radical mastectomy on clinical effect and tumor markers in patients with breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 104-109.

References

［1］徐广伟,周姝,任林广,等.乳腺癌患者外周血淋巴细胞10种表型的检测及其意义［J］.中国妇幼保健,2014,29(9):1427-1430.
［2］黄榕权,谢燕清,张雅洁,等.MMP-2、MMP-9和VEGF-D在乳腺癌中的表达及其与肿瘤淋巴管新生的关系［J］.广东医学,2014,35(13):2072-2074.
［3］Shia WC, Chen DR, Huang YL, et al. Effectiveness of evaluating tumor vascularization using 3D power Doppler ultrasound with high-definition flow technology in the prediction of the response to neoadjuvant chemotherapy for T2 breast cancer: a preliminary report［J］. Phys Med Biol,2015,60(19):7763-7778.
［4］刘志勇,李宝江.乳腺癌新辅助化疗中循环肿瘤细胞的动态变化及疗效观察［J］.中国肿瘤临床,2013,40(23):1431-1435.
［5］于辰华,陆苏,刘红，等.乳腺癌新辅助化疗疗效与疾病预后研究进展［J］.天津医药,2016,44(12):1518-1520.
［6］张崇建,秦丽,王璐，等.乳腺癌新辅助化疗疗效的影响因素及预后分析［J］.中国老年学杂志,2016,36(3):636-637.
［7］曾峰,谭永嘉,曾庆良，等.TE方案新辅助化疗在乳腺癌治疗中的应用观察及机制探讨［J］.山东医药,2012,52(2):62-63.
［8］沈雷.乳腺癌新辅助化疗的研究进展［J］.复旦学报（医学版）,2016,43(2):244-248.
［9］刘钊,尉承泽,黄焰,等.乳腺癌新辅助化疗疗效与临床特征的相关性研究［J］.军事医学,2013,37(9):700-703.
［10］庞涛,庞博文. 新辅助化疗联合腔镜对85例乳腺癌改良根治术的影响观察［J］. 贵州医药,2017,41(7):735-737.
［11］张忠林,吴洋,陈锐,等. 乳腺癌改良根治术联合新辅助化疗对乳腺癌患者的应用价值［J］. 西部医学,2016,28(7):928-931.
［12］李永峰,陈杰,谢尚闹,等. TE新辅助化疗联合乳腺癌改良根治术治疗乳腺癌效果观察［J］. 中国乡村医药,2015,22(24):26-27+31.
［13］冯宇,赵霞,吕淑贞，等.表柔比星联合多西他赛新辅助化疗对乳腺癌患者癌组织 Ki-67表达的影响及意义［J］.山东医药,2016,56(24):63-65.
［14］郭莉,李迅,杨顺娥，等.TE 及 NE 方案在乳腺癌新辅助化疗中疗效及毒副反应的比较［J］.广东医学,2014,35(7):1039-1041,1042.
［15］陈峰,沈霞平,边林莉，等.TE方案与TEC方案在乳腺癌新辅助化疗中的疗效比较［J］.中国肿瘤,2013,22(11):926-930.
［16］Boccardo F, Amadori D, Guglielmini P,et al. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer［J］. Oncology，2010，78(3/4):274-281.

[1]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[2]	CHEN Minfang, CHEN Lihua, XIE Liyun, XU Fenfen, XIA Aixiao, LIN Zhong. Preparation and the effect of antitumor of DNA plasmid lipidosome vaccine based VEGFR2 extracellular region by immunization activated in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 24-29.
[3]	XIE Fangying, CHEN Zheli, GAO Yuelan. Effects of Yiqi Yangyinshengji recipe on rats with recurrent oral ulcer and its effect on mucosal inflammatory factors and immune function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 20-26.
[4]	YUAN Jing, SUN Jingxue, HUANG Daiqiang, YUAN Lin, DING Dengfeng. Effects of low dose dexmedetomidine combined with ulinastatin on immune function and stress response in patients with lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 83-88.
[5]	CAO Linzhong, WANG Xiaomin, ZHANG Hulin, GUO Chenglong, SU Lianglei, LIU Xinyu. Effects of Shenggu zaizao pills on VEGF and FLT-1 expression in steroid-induced avascular necrosis of femoral head in rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 874-880.
[6]	LI Minjiang, CHEN Dong, CHEN Wenbin. Effects of beta-adrenergic receptor blockers and COX-2 inhibitors on liver metastasis of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 893-899.
[7]	CHENG Xiaolong, HU Kunmei, HU Haoran，XU Hanghang, YANG Jieren, HAN Jun. Effects of Chinese medicine Yuxia capsule on renal fibrosis in spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 632-639.
[8]	LI Rui，KONG Yan，LIU Zenghui，LUO Shengyong. Effects of Rufuning granules on hormone levels and the expression of VEGF protein in mammary gland hyperplasia rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 138-142.
[9]	WANG Ting, CHEN Ke, ZHOU Changping, WANG Yiqiao, LU Xianfu, LI Yuanhai. Effects of precise anesthesia on perioperative cellular immune function in patients undergoing robot-assisted laparoscopic radical prostatectomy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 175-179.
[10]	CHEN Xiangyan, CHEN Cong, SUN Yun, ZHANG Hong, GAO Chuchu, CHEN Shu. Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1408-1414.
[11]	ZHAO Pengcheng, ZHANG Chao. Effects of propofol combined with sevoflurane on kidney function and immune function in patients with cirrhosis after splenectomy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1276-1281.
[12]	CHEN Zhou, HUANG He, CHEN Qiyu. Effects of Shenfu injection on the quality of life and immune function on patients with breast cancer after chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1159-1164.
[13]	WU Miao, LIU Yonglin, CAI Yunya. Therapeutic effect of fluorouracil coated with interferon injection combined with liquid nitrogen cryotherapy in the treatment of verruca plantaris and influence on immune function in patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 312-315.
[14]	YU Qinyun, ZHAN Xiaofeng, HUANG Yan. Effects of formononetin on P38MAPK/MMP-9 signaling pathway in ovariectomized rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1371-1376.
[15]	LUO Lingling, TENG Chengzhi, LI Xiaoxiao, PAN Danfeng. Clinical trial of azithromycin combined with ambroxol hydrochloride in treatment of mycoplasma pneumonia children with acute bronchial pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1278-1282.